ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°, °¡¼öº°, Åõ¿© °æ·Îº°, ¿¬·ÉÃþº°, ±â¼úº°, À¯Åë ä³Îº°, Áö¿ªº°
Influenza Vaccines Market, By Vaccine Type, By Valency, By Route of Administration, By Age Group, By Technology, By Distribution Channel, By Geography
»óǰÄÚµå
:
1672819
¸®¼Ä¡»ç
:
Coherent Market Insights
¹ßÇàÀÏ
:
2025³â 02¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹®
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº 2025³â¿¡´Â 89¾ï 1,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ°í, 2032³â¿¡´Â 145¾ï 9,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025³âºÎÅÍ 2032³â±îÁö ¿¬Æò±Õ ¼ºÀå·ü(CAGR) 7.3%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
º¸°í ¹üÀ§ |
º¸°í¼ ¼¼ºÎÁ¤º¸ |
±âÁØ ¿¬µµ |
2024³â |
½ÃÀå ±Ô¸ð(2025³â) |
89¾ï 1,000¸¸ ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ |
2020-2024³â |
¿¹Ãø ±â°£ |
2025-2032³â |
¿¹Ãø ±â°£ CAGR(2025-2032³â) |
7.30% |
±Ý¾× ¿¹Ãø(2032³â) |
145¾ï 9,000¸¸ ´Þ·¯ |
±×¸². ÀÎÇ÷翣ÀÚ ¹é½Å Áö¿ªº° ½ÃÀå Á¡À¯À²(%)(2025³â)

ÀÎÇ÷翣ÀÚ ¹é½ÅÀº ¼ö½Ê³âµ¿¾È ¿¹¹æ ÀÇ·áÀÇ Áß¿äÇÑ ¿ä¼Ò°¡ µÇ¾ú½À´Ï´Ù. ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½º´Â Á¤±âÀûÀ¸·Î º¯ÀÌ ¹× ÁøÈÇϱ⠶§¹®¿¡ ¸Å³â Ãֽйé½ÅÀ» °³¹ßÇÒ Çʿ䰡 ÀÖ½À´Ï´Ù. ¹é½ÅÀº º¯ÈÇÏ´Â ¹ÙÀÌ·¯½º¿¡ ´ëÇÑ ½ÅüÀÇ ¸é¿ª ¹ÝÀÀÀ» Çâ»ó½ÃŰ´Â ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ¹é½ÅÀº °¨½Ã ¹× ±âŸ °úÇÐÀû Á¶»ç¸¦ ÅëÇØ ¾î´À Áö¿ª¿¡¼µµ ´ÙÀ½ ÀÎÇ÷翣ÀÚ ½ÃÁð¿¡ °¡Àå À¯ÇàÇÒ °ÍÀ¸·Î ÆÇ´ÜµÇ´Â 3-4ÁÖ(ƯÁ¤ ÀÎÇ÷翣ÀÚ ½ÃÁð¿¡ »ç¿ëµÇ´Â ¹é½Å À¯Çü¿¡ µû¶ó ´Ù¸§)¿¡ ´ëÇÑ ¸é¿ªÀ» °ÈÇϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀº °èÀý¼º ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ÀǽÄÀÌ ³ô¾ÆÁö°í, ½Å±â¼ú ä¿ë, ÀÇ·á±â°ü¿¡ ÀÇÇÑ ¹é½Å Á¢Á¾ °¡À̵å¶óÀÎ È®´ë, ¼¼°è Á¤ºÎ Áö¿øÀÇ °íÁ¶¿¡ ÀÇÇØ Áö³ ¼ö³â°£ ¾ÈÁ¤µÈ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù.
½ÃÀå ¿ªÇÐ
¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀÇ ¼ºÀåÀº ÀÎÇ÷翣ÀÚÀÇ À¯Çà Áõ°¡, ±¹Á¦ º¸°Ç±â±¸°¡ Á¤ÇÑ ¹é½Å Á¢Á¾ °¡À̵å¶óÀΠä¿ë È®´ë, ¹é½Å Á¢Á¾¿¡ ´ëÇÑ ÀǽÄÀÇ °íÁ¶, ½ÅÁ¦Ç° Ãâ½Ã, ÀçÁ¶ÇÕ ±â¼ú ¹é½Å¿¡ ´ëÇÑ ¼±È£µµ Áõ°¡, ÁÖ¿ä ±â¾÷ÀÇ Áö¸®Àû ¹üÀ§ È®´ë µî ´Ù¾çÇÑ ¿äÀο¡ ÀÇÇØ °ßÀεǰí ÀÖ½À´Ï´Ù. ±×·¯³ª, 4°¡ ÀÎÇ÷翣ÀÚ ¹é½ÅÀÇ °³¹ß¿¡ µå´Â ³ôÀº ¿¬±¸°³¹ßºñ, ½Å¹é½ÅÀÇ ½ÂÀο¡ Àû¿ëµÇ´Â ¾ö°ÝÇÑ ±ÔÁ¦ °¡À̵å¶óÀÎ, ÀÎÇ÷翣ÀÚ ¹ÙÀÌ·¯½ºÁÖÀÇ Ç׿ø µå¸®ÇÁÆ®¿¡ ÀÇÇØ ¹é½Å ³»¼ºÀÌ »ý±â´Â °Í µîÀÌ ½ÃÀå ¼ºÀåÀÇ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ½ÃÀå °ü°èÀÚ´Â ÀÇ·á ÀÎÇÁ¶ó°¡ °³¼±µÇ°í °¡Ã³ºÐ ¼ÒµæÀÌ Áõ°¡ÇÏ´Â ½ÅÈï±¹¿¡ ºñÁî´Ï½º ±âȸ°¡ ÀÖ´Ù°í »ý°¢ÇÕ´Ï´Ù. Á¦Á¶¾÷ü´Â ¶ÇÇÑ ¿©·¯ ÀÎÇ÷翣ÀÚ ±ÕÁÖ¿¡ ´ëÇÑ Áö¼ÓÀûÀÎ ¿¹¹æ È¿°ú¸¦ Áö´Ñ ´ÙÀç´Ù´ÉÇÑ ¹é½ÅÀ» °³¹ßÇϱâ À§ÇØ ³ë·ÂÇϰí ÀÖ½À´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
- º» º¸°í¼¿¡¼´Â ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀåÀ» »ó¼¼ÇÏ°Ô ºÐ¼®ÇÏ¿© 2024³âÀ» ±âÁØ¿¬µµ·Î ÇÑ ¿¹Ãø±â°£(2025-2032³â) ½ÃÀå ±Ô¸ð(10¾ï ´Þ·¯) ¹× ¿¬°£ Æò±Õ ¼ºÀå·ü(CAGR%)À» Á¦°øÇÕ´Ï´Ù.
- ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®¿¡ °ÉÄ£ ÀáÀçÀûÀÎ ¼öÀÍ ±âȸ¸¦ ¹àÈ÷°í ÀÌ ½ÃÀåÀÇ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È Çà·ÄÀ» ¼³¸íÇÕ´Ï´Ù.
- ¶ÇÇÑ ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ª¿¡ ÀÇÇÑ Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤¿ëÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ Áß¿äÇÑ ÀλçÀÌÆ®µµ Á¦°øÇÕ´Ï´Ù.
- ¿£ÅÍÇÁ¶óÀÌÁî ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ¸Å°³º¯¼ö¸¦ ±â¹ÝÀ¸·Î Àü ¼¼°è ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå¿¡¼ ÁÖ¿ä ±â¾÷ ÇÁ·ÎÆÄÀÏÀ» Á¦°øÇÕ´Ï´Ù.
- ÀÌ º¸°í¼ÀÇ ÀλçÀÌÆ®¸¦ ÅëÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ¿Í ±â¾÷ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° Ãâ½Ã, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ ´ëÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù.
- ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå º¸°í¼´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü°¡ÀÚ, À繫 ºÐ¼®°¡ µî ÀÌ »ê¾÷ÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î ÇÕ´Ï´Ù.
- ÀÌÇØ°ü°èÀÚµéÀº ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÕ´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»çÀÇ ¸ñÀû ¹× ÀüÁ¦Á¶°Ç
Á¦2Àå ½ÃÀå Àü¸Á
- º¸°í¼ ¼³¸í
- ÁÖ¿ä ¿ä¾à
- Coherent Opportunity Map (COM)
Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦ ¹× µ¿Ç⠺м®
- ½ÃÀå ¿ªÇÐ
- ¼ºÀå ÃËÁø¿äÀÎ
- ¼ºÀå ¾ïÁ¦¿äÀÎ
- ±âȸ
- ¿µÇ⠺м®
- »ê¾÷ µ¿Çâ
- ±ÔÁ¦ ½Ã³ª¸®¿À
- ÃÖ±Ù Á¦Ç° ½ÂÀÎ ¹× ¹ß¸Å
- PEST ºÐ¼®
- Porter's Five Forces ºÐ¼®
Á¦4Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : Äڷγª ¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ
- ¼ö¿ä¿¡ ¹ÌÄ¡´Â ¿µÇâ
- ÀÇ·á¿¡ ¹ÌÄ¡´Â ¿µÇâ
- ¿ªÇÐ
Á¦5Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : ¹é½Å À¯Çüº°(2020-2032³â)(10¾ï ´Þ·¯)
Á¦6Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : °¡¼öº°(2020-2032³â)(10¾ï ´Þ·¯)
Á¦7Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : Åõ¿© °æ·Îº°(2020-2032³â)(10¾ï ´Þ·¯)
Á¦8Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : ¿¬·ÉÃþº°(2020-2032³â)(10¾ï ´Þ·¯)
Á¦9Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : ±â¼úº°(2020-2032³â)(10¾ï ´Þ·¯)
- ¼¹®
- °è¶õ ±â¹Ý ÀÎÇ÷翣ÀÚ ¹é½Å
- ¼¼Æ÷ ¹è¾ç¿¡ ÀÇÇÑ ÀÎÇ÷翣ÀÚ ¹é½Å
- ÀçÁ¶ÇÕ ÀÎÇ÷翣ÀÚ ¹é½Å
Á¦10Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : À¯Åë ä³Îº°(2020-2032³â)(10¾ï ´Þ·¯)
Á¦11Àå ¼¼°èÀÇ ÀÎÇ÷翣ÀÚ ¹é½Å ½ÃÀå : Áö¿ªº°(2020-2032³â)(10¾ï ´Þ·¯)
- ¼¹®
- ºÏ¹Ì
- ¶óƾ¾Æ¸Þ¸®Ä«
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- 秵- ¾ÆÇÁ¸®Ä«
- ³²¾ÆÇÁ¸®Ä«
- Áß¾Ó ¾ÆÇÁ¸®Ä«
- ºÏ¾ÆÇÁ¸®Ä«
Á¦12Àå °æÀï ±¸µµ
- È÷Æ®¸Ê ºÐ¼®
- ½ÃÀå Á¡À¯À² ºÐ¼®
- CSL Seqirus
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen, Inc.
- Moderna, Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- Daiichi Sankyo
- Bharat BIoTech
- Sinovac BIoTech
- Solaris Vaccines
Á¦13Àå ¾Ö³Î¸®½ºÆ®ÀÇ ½ÃÁ¡
- À¶¼º ¹× ¼èÅð
- ÀϰüÇü ±âȸ ¸Ê
Á¦14Àå Âü°í¹®Çå ¹× Á¶»ç¹æ¹ý
AJY
¿µ¹® ¸ñÂ÷
Global Influenza Vaccines Market is estimated to be valued at USD 8.91 Bn in 2025 and is expected to reach USD 14.59 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.3% from 2025 to 2032.
Report Coverage |
Report Details |
Base Year: |
2024 |
Market Size in 2025: |
USD 8.91 Bn |
Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: |
7.30% |
2032 Value Projection: |
USD 14.59 Bn |
Figure. Influenza Vaccines Market Share (%), By Region 2025

Influenza vaccines have been an important element of preventive healthcare for decades. The influenza viruses have the ability to mutate and evolve regularly, necessitating the development of updated vaccines each year. The vaccines work to boost the body's immune response to these changing viruses. They are designed to immunize against the three or four strains (depending on the vaccine type used for a particular flu season) that surveillance and other scientific studies have determined are most likely to be in circulation for the upcoming flu season in any given region. The global influenza vaccines market has witnessed steady growth over the past few years due to the growing awareness about seasonal vaccination, introduction of novel technologies, expansion of vaccination guidelines by healthcare organizations, and rising government support worldwide.
Market Dynamics:
The global influenza vaccines market growth is driven by various factors such as the increasing prevalence of influenza, growing adoption of vaccination guidelines set by international health organizations, rising awareness about vaccination, new product launches, growing preference for recombinant technology vaccines, and expansion in geographical reach of major players. However, the market growth can be challenging due to high R&D costs involved for development of quadrivalent influenza vaccines, stringent regulatory guidelines for approval of new vaccines and vaccine resistance arising due to antigenic drift of influenza virus strains. The market players see opportunities in emerging countries owing to improving healthcare infrastructure and rising disposable incomes. Manufacturers are also working on the development of universal influenza vaccine with durable protection against multiple flu strains.
Key Features of the Study:
- This report provides an in-depth analysis of the global influenza vaccines market, and provides market size (USD BN) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year.
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global influenza vaccines market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study includes Seqirus, GlaxoSmithKline plc, Sanofi, AstraZeneca, FluGen Inc., Moderna Inc., Biocryst Pharmaceuticals Inc., CPL Biologicals Pvt. Ltd., CureVac AG, OSIVAX, Solaris Vaccines, Pfizer, CSL, Daiichi Sankyo, Bharat Biotech, and Sinovac Biotech.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global influenza vaccines market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global influenza vaccines market.
Market Segmentation
- Vaccine Type:
- Inactivated
- Live Attenuated
- Valency:
- Route of Administration:
- Age Group:
- Technology:
- Egg-Based Flu Vaccines
- Cell Culture-Based Flu Vaccines
- Recombinant Flu Vaccines
- Distribution Channel:
- Regional:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Seqirus
- GlaxoSmithKline plc
- Sanofi
- AstraZeneca
- FluGen Inc.
- Moderna Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- CSL
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snapshot, By Vaccine Type
- Market Snapshot, By Valency
- Market Snapshot, By Route of Administration
- Market Snapshot, By Age Group
- Market Snapshot, By Technology
- Market Snapshot, By Distribution Channel
- Market Snapshot, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Restraints
- Opportunity
- Impact Analysis
- Key Developments
- Industry Trends
- Regulatory Scenario
- Recent Product Approval/Launches
- PEST Analysis
- Porter's Analysis
4. Global Influenza Vaccines Market- Impact of Coronavirus (COVID-19) Pandemic
- Impact on Demand
- Impact on Healthcare
- Epidemiology
5. Global Influenza Vaccines Market, By Vaccine Type, 2020 - 2032, (USD BN)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Inactivated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
- Live Attenuated
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
6. Global Influenza Vaccines Market, By Valency, 2020 - 2032, (USD BN)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Quadrivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
- Trivalent
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
7. Global Influenza Vaccines Market, By Route of Administration, 2020 - 2032, (USD BN)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Injection
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
- Nasal Spray
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (USD BN)
8. Global Influenza Vaccines Market, By Age Group, 2020 - 2032, (USD BN)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Pediatrics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
- Adults
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
9. Global Influenza Vaccines Market, By Technology, 2020 - 2032, (USD BN)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Egg-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
- Cell Culture-Based Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
- Recombinant Flu Vaccines
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
10. Global Influenza Vaccines Market, By Distribution Channel, 2020 - 2032, (USD BN)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2020 - 2032
- Segment Trends
- Public
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
- Private
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 - 2032, (USD BN)
11. Global Influenza Vaccines Market, By Region, 2020 - 2032 (USD BN)
- Introduction
- Market Share Analysis, By Region, 2025 and 2032(%)
- Y-o-Y Growth Analysis, For Regions, 2020 - 2032
- Regional Trends
- North America
- Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
- Latin America
- Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Country, 2020 - 2032 (USD BN)
- GCC
- Israel
- Rest of Middle East
- Africa
- Market Size and Forecast, By Vaccine Type, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Valency, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Route of Administration, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Age Group, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Technology, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Distribution Channel, 2020 - 2032 (USD BN)
- Market Size and Forecast, By Region/Country, 2020 - 2032 (USD BN)
- South Africa
- Central Africa
- North Africa
12. Competitive Landscape
- Heat Map Analysis
- Market Share Analysis
- CSL Seqirus
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AstraZeneca
- FluGen, Inc.
- Moderna, Inc.
- Biocryst Pharmaceuticals Inc.
- CPL Biologicals Pvt. Ltd.
- CureVac AG
- OSIVAX
- Solaris Vaccines
- Pfizer
- Daiichi Sankyo
- Bharat Biotech
- Sinovac Biotech
- Solaris Vaccines
13. Analyst View
- Wheel of Fortune
- Analyst View
- Coherent Opportunity Map
14. References and Research Methodology
- References
- Research Methodology
- About us and Sales Contact
°ü·ÃÀÚ·á